Reby Advisors’s GSK GSK Stock Holding History

Reby Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$62K	Buy	+1,357	New	+$62.3K	0.02%	201

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Reby Advisors's GSK Position: Q4 2020 in Review

Reby Advisors opened a new position in GSK (GSK) in Q4 2020: 1,357 shares worth $62K. The stake represents 0.02% of the portfolio and ranks #201 among its holdings.

818 funds tracked by Wall St. Rank hold GSK as of Q4 2020.

Reby Advisors held 1,357 shares of GSK worth $62K as of Q4 2020.
GSK was a new Reby Advisors position in Q4 2020.
GSK made up 0.02% of Reby Advisors's portfolio in Q4 2020, its #201 holding.
818 funds tracked by Wall St. Rank held GSK as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.